Understand the source comparison
Ranked Comparison: Mechanism, Dosing, and Research Evidence
BPC-157 VEGF upregulation for mucosal repair, angiogenesis in damaged tissue 250–500 mcg SC daily or 1–2 mg oral daily 7–14 days for measurable barrier improvement Rodent colitis models show 40–60% lesion reduction in 14 days; human case series report symptom
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation for mucosal repair, angiogenesis in damaged tissue
- 250–500 mcg SC daily or 1–2 mg oral daily
- 7–14 days for measurable barrier improvement
- Rodent colitis models show 40–60% lesion reduction in 14 days; human case series report symptom improvement in IBD patients within 3 weeks
- Best first-line option for acute mucosal damage or post-inflammatory repair—pairs well with KPV to address both tissue and inflammation
- KPV
- NF-κB inhibition in enterocytes, suppression of TNF-α and IL-6
- 500 mcg oral twice daily
- 48–72 hours for inflammation marker reduction
- DSS-induced colitis models show 35% reduction in inflammation scores; oral bioavailability confirmed in mucosal tissue biopsies
- Essential for controlling active inflammation—use concurrently with barrier repair peptides, not as monotherapy
- Thymalin
- T-cell modulation in GALT, restoration of Th1/Th2 balance
- 10 mg SC every 3–5 days for 4–6 weeks
- 3–4 weeks for immune recalibration
- Human trials in autoimmune conditions show restored T-cell ratios after 6-week protocols; indirect gut benefit through systemic immune balance
- Long-term recalibration tool—not for acute flare management, but critical for preventing relapse in chronic gut conditions
- LL-37 (Cathelicidin)
- Antimicrobial peptide, modulates gut microbiome composition
- 2–5 mg oral or topical mucosal application
- Variable—depends on baseline dysbiosis severity
- In vitro studies show broad-spectrum activity against pathogenic bacteria; limited human gut-specific data
- Emerging research area—mechanism is sound but clinical dosing protocols remain under investigation
- Cartalax
- Regulation of gastric acid secretion, cytoprotection in stomach lining
- 10–20 mcg SC daily for 10–14 days
- 5–7 days for gastric symptom improvement
- Rodent models show reduced gastric ulcer formation; limited human trials in functional dyspepsia
- Useful for upper GI protection but not a direct gut barrier repair compound—consider for gastric issues separate from intestinal permeability